In focus
Menarini and Ryvu Report First Clinical Activity for Dapolsertib in Heavily Pretreated Aggressive B-cell Lymphoma
Initial Phase II JASPIS-01 results show clinical activity for dapolsertib monotherapy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma patients who have exhausted standard options. The data will be presented in a poster session at the 2026 ASH Annual Meeting in New Orleans.
Read the story